Dr. Rampal on the Importance of Clinical Trial Enrollment in Myelofibrosis

Raajit K. Rampal, MD, PhD, hematologic oncologist, associate attending physician, Memorial Sloan Kettering Cancer Center, discusses the importance of clinical trial enrollment in patients with myelofibrosis.

Given the number of ongoing clinical trials, it is important that physicians treating patients with myelofibrosis encourage enrollment for these trials, Rampal says. Enrollment is important because it is likely that many of the drugs that are currently under investigation will move forward to approval and change the standard of care, Rampal explains.

Moreover, the days of JAK inhibitor monotherapy may be limited and will only pertain to a select patient population for whom that is the appropriate treatment, Rampal continues. Beyond that, there are multiple combinations that if proven successful will alter patient treatment, Rampal concludes.